Literature DB >> 27343070

PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?

Klaus Lehmann-Horn1, Horst Penkert1, Peter Grein1, Ulrich Leppmeier1, Sarah Teuber-Hanselmann1, Bernhard Hemmer1, Achim Berthele2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27343070     DOI： 10.1212/WNL.0000000000002900

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  18 in total

1.  Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.

Authors:  Luca Prosperini; Cristina Scarpazza; Luisa Imberti; Cinzia Cordioli; Nicola De Rossi; Ruggero Capra
Journal:  J Neurovirol       Date:  2017-08-08       Impact factor: 2.643

2.  Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.

Authors:  Jeremias Motte; Janina Kneiphof; Katrin Straßburger-Krogias; Anja Klasing; Ortwin Adams; Aiden Haghikia; Ralf Gold
Journal:  J Neurol       Date:  2018-06-15       Impact factor: 4.849

Review 3.  Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Elena Grebenciucova; Amy Pruitt
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-22       Impact factor: 5.081

Review 4.  Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Authors:  Robbert-Jan Gieselbach; Annemarie H Muller-Hansma; Martijn T Wijburg; Marjolein S de Bruin-Weller; Bob W van Oosten; Dennis J Nieuwkamp; Frank E Coenjaerts; Mike P Wattjes; Jean-Luc Murk
Journal:  J Neurol       Date:  2017-05-23       Impact factor: 4.849

Review 5.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 6.  Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

7.  Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.

Authors:  Fabian Sierra Morales; Igor J Koralnik; Shiva Gautam; Soleil Samaan; Jacob A Sloane
Journal:  J Neurol       Date:  2019-10-03       Impact factor: 4.849

8.  Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Authors:  Mahtab Ghadiri; Ayman Rezk; Rui Li; Ashley Evans; Felix Luessi; Frauke Zipp; Paul S Giacomini; Jack Antel; Amit Bar-Or
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-03-23

Review 9.  Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.

Authors:  Allison Lm Jordan; Jennifer Yang; Caitlyn J Fisher; Michael K Racke; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2020-08-18       Impact factor: 6.312

Review 10.  Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.

Authors:  Elizabeth A Mills; Magdalena A Ogrodnik; Andrew Plave; Yang Mao-Draayer
Journal:  Front Neurol       Date:  2018-01-23       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.